We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Vascular Graft Infections (VASGRA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01821664
Recruitment Status : Recruiting
First Posted : April 1, 2013
Last Update Posted : May 6, 2015
Schweizerischer Nationalfonds
Information provided by (Responsible Party):
University of Zurich

March 7, 2013
April 1, 2013
May 6, 2015
May 2013
March 2023   (Final data collection date for primary outcome measure)
Vascular graft infection [ Time Frame: within 10 years ]
Persons are followed up after vascular graft surgery.
Same as current
Complete list of historical versions of study NCT01821664 on ClinicalTrials.gov Archive Site
  • Bleeding [ Time Frame: 10 years ]
  • Foreign body reaction [ Time Frame: 10 years ]
  • All cause- mortality [ Time Frame: 10 years ]
Same as current
Not Provided
Not Provided
Vascular Graft Infections
Vascular Graft Infections - Epidemiology, Best Treatment Options, Imaging Modalities and Impact of Negative Pressure Wound Therapy
Background: Vascular grafts are increasingly implanted due to an increasing prevalence of atherosclerosis and diabetes, and about 1-6% of vascular procedures are complicated by infection. Mortality attributable to prosthetic vascular graft infections (PVGI) is high. However, there are almost no data regarding best treatment options of such complicated infections. Most recommendations are based on expert opinion and not on clinical trials or cohort observational data analyses. Evaluating infectious and other complications after vascular surgery procedures are important, and additionally, such studies may offer insights for quality improvement and improved patient outcomes. With the first aim investigators will establish an infrastructure for studying PVGI in Zurich. Investigators will take advantage of the Swissvasc registry, a central registry which collects preoperative, operative and discharge data regarding the index vascular surgical interventions. They will create a prospective observational cohort database of all patients who receive a vascular graft (peripheral, aortic, vein) at the University hospital of Zurich (VASGRA Cohort A). Patients with a PVGI will be included in VASGRA Cohort B and followed up using a flow chart with a focus on the course of this infectious complication. Additionally, investigators will establish a biobank with the collection of tissue- and blood samples of patients with PVGI. With the second aim researchers will investigate different diagnostic, clinical and therapeutic research questions nested in the VASGRA Cohort. Firstly, they will address epidemiological questions, such as: determine the incidence and outcome of complications after vascular graft placement; determine risk factors, best treatment strategies and outcome of PVGI, and determine the influence of different antibiotic regimens on the outcome of PVGI due to different bacterial pathogens. Secondly, investigators will determine the accuracy of different imaging techniques (PET/CT and MRI) for the diagnosis of PVGI, and their individual role for the assessment of treatment response. Thirdly, investigators will evaluate the bacterial diversity of vascular wound infections using 16s r-Ribonucleic acid (RNA)amplification, and investigators will explore whether this bacterial diversity does predict disease progression. Here, investigators will also study the impact of negative pressure wound therapy (NPWT) on bacterial diversity in the treatment course of PVGI. Fourthly, investigators will look for cut-off levels of relevant blood leucocytes count, C-reactive protein and procalcitonin raising suspicion of a PVGI. Lastly, investigators will look at histopathological features of excised vascular grafts. Expected value of the project: Results from the proposed study are an important contribution to the field, based on the large sample size, longitudinal design and by unifying clinical and epidemiological science. The very well characterized patient groups and the close connection between vascular surgeons, infectious disease specialists, specialists in nuclear medicine and microbiologist will help to investigate PVGI in depths. Investigators hope to be able to develop guidelines regarding best diagnostic modalities and treatment options in case of vascular graft infections. In the future we plan to examine bacteria retrieved from the PVGI in the laboratory in detail. The recovered bacteria will be examined for antimicrobial susceptibility and their capability to form biofilms. Furthermore investigators will examine how bacterial recovery form explanted grafts could be optimized.
Not Provided
Observational [Patient Registry]
Observational Model: Cohort
Time Perspective: Prospective
10 Years
Not Provided
Non-Probability Sample
All patients with a vascular surgery at the University hospital will be included in the study.
Prosthetic Vascular Graft Infection
Device: Prosthetic vascular graft
Implantation of a prosthetic vascular graft
Other Names:
  • Valsalva Graft, Gelwave TM
  • Subclavia Graft, Gelwave TM
  • Longer Ante-Flo Offset branch, Gelwave TM
  • Lupiae Branched Graft, Gelwave TM
  • 4 Branched Plexus, Gelwave TM
  • Bifurcate, Gelwave TM soft
  • Subclavia Graft straight, Gelwave TM soft
  • Intergard woven straight, Intervascular "Maquet Getinge Group"
  • Intergard woven hemabridge, Intervascular "Maquet Getinge Group"
  • Intergard woven Aortic Arch, Intervascular "Maquet Getinge Group"
  • Intergard Silver Knitted Bifurcation, Intervascular "Maquet Getinge Group"
  • Intergard Silver Knitted Straight, Intervascular "Maquet Getinge Group"
  • InterGard TM knitted Bifurcation, Intervascular "Maquet Getinge Group"
  • FlowLine Bipore r Heparin ePTFE Vascular Graft, Jotec r GmbH
  • ePTFE Vascular Graft Regular Wall flex, IMPRA r
  • ePTFE Vascular Graft Thin Wall flex, IMPRA r
  • ePTFE Vascular Graft Regular Wall straight, IMPRA r
  • Gore-Tex Stretch Vascular Graft standard Wall Eptfe, W.L. Gore & Associates, Inl
Prosthetic vascular graft implantation, follow up
Intervention: Device: Prosthetic vascular graft
Husmann L, Sah BR, Scherrer A, Burger IA, Stolzmann P, Weber R, Rancic Z, Mayer D, Hasse B; VASGRA Cohort. ¹⁸F-FDG PET/CT for Therapy Control in Vascular Graft Infections: A First Feasibility Study. J Nucl Med. 2015 Jul;56(7):1024-9. doi: 10.2967/jnumed.115.156265. Epub 2015 May 14.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2023
March 2023   (Final data collection date for primary outcome measure)

Inclusion criteria:

Control patients:

- Vascular graft surgery (peripheral, aortic, vein)

Case patients:

  • Patients with previous primary implantation of an aortic or peripheral vascular implant and suspicion of PVGI
  • Age >18 years
  • Written informed consent

Exclusion criteria:

  • Drug or alcohol abuse
  • Involvement in a conflicting clinical trial (investigational drug)
  • Inability to follow the procedures of the cohort, e.g. due to language problems, psychological disorders or dementia of the subject
  • Known or suspected non-compliance
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact: Barbara Hasse, MD +41 (0)44 255 11 11 barbara.hasse@usz.ch
KEK-ZH-Nr. 2012-0583
Not Provided
Not Provided
Not Provided
University of Zurich
University of Zurich
Schweizerischer Nationalfonds
Principal Investigator: Barbara Hasse, MD University Hospital Zurich, Div of Infectious Diseases and Hospital Epidemiology
University of Zurich
May 2015